|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.88 HKD | +4.76% |
|
-6.53% | -8.69% |
| 03-04 | Abbisko Doses First Patient in Tumor Drug Trial | MT |
| 03-03 | Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share | RE |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Revenues | - | 22.68M | - | 19.06M | 504M | |
Other Revenues, Total | 7.3M | - | - | - | - | |
Total Revenues | 7.3M | 22.68M | - | 19.06M | 504M | |
Gross Profit | 7.3M | 22.68M | - | 19.06M | 504M | |
Selling General & Admin Expenses, Total | 21.17M | 125M | 118M | 96.4M | 74.21M | |
R&D Expenses | 133M | 226M | 379M | 434M | 451M | |
Other Operating Expenses, Total | 154M | 351M | 497M | 530M | 526M | |
Operating Income | -147M | -328M | -497M | -511M | -21.59M | |
Interest Expense, Total | -338K | -959K | -2.68M | -2.17M | -1.61M | |
Interest And Investment Income | 11.44M | 16.94M | - | 65.49M | 89.1M | |
Net Interest Expenses | 11.1M | 15.98M | -2.68M | 63.32M | 87.49M | |
Currency Exchange Gains (Loss) | - | 6.67M | -41.3M | -5.6M | 1.8M | |
Other Non Operating Income (Expenses) | -571M | 14M | 45.56M | 21.07M | 10.34M | |
EBT, Excl. Unusual Items | -707M | -292M | -496M | -432M | 78.03M | |
Gain (Loss) On Sale Of Investments | - | 5.9M | - | 706K | - | |
Other Unusual Items | - | -1.52B | - | - | - | |
EBT, Incl. Unusual Items | -707M | -1.81B | -496M | -432M | 78.03M | |
Income Tax Expense | - | - | - | - | 49.73M | |
Earnings From Continuing Operations | -707M | -1.81B | -496M | -432M | 28.3M | |
Net Income to Company | -707M | -1.81B | -496M | -432M | 28.3M | |
Net Income - (IS) | -707M | -1.81B | -496M | -432M | 28.3M | |
Net Income to Common Incl Extra Items | -707M | -1.81B | -496M | -432M | 28.3M | |
Net Income to Common Excl. Extra Items | -707M | -1.81B | -496M | -432M | 28.3M | |
Per Share Items | ||||||
Net EPS - Basic | -7.12 | -7.71 | -0.8 | -0.67 | 0.04 | |
Basic EPS - Continuing Operations | -7.12 | -7.71 | -0.8 | -0.67 | 0.04 | |
Basic Weighted Average Shares Outstanding | 99.19M | 235M | 621M | 647M | 634M | |
Net EPS - Diluted | -7.12 | -7.71 | -0.8 | -0.67 | 0.04 | |
Diluted EPS - Continuing Operations | -7.12 | -7.71 | -0.8 | -0.67 | 0.04 | |
Diluted Weighted Average Shares Outstanding | 99.19M | 235M | 621M | 647M | 650M | |
Normalized Basic EPS | -4.45 | -0.78 | -0.5 | -0.42 | 0.08 | |
Normalized Diluted EPS | -4.45 | -0.78 | -0.5 | -0.42 | 0.08 | |
Supplemental Items | ||||||
EBITDA | -143M | -323M | -493M | -505M | -10.79M | |
EBITA | -146M | -328M | -497M | -511M | -21.59M | |
EBIT | -147M | -328M | -497M | -511M | -21.59M | |
EBITDAR | - | - | -491M | -504M | -10.02M | |
Effective Tax Rate - (Ratio) | - | - | - | - | 63.73 | |
Current Foreign Taxes | - | - | - | - | 49.73M | |
Total Current Taxes | - | - | - | - | 49.73M | |
Normalized Net Income | -442M | -182M | -310M | -270M | 48.77M | |
Interest on Long-Term Debt | 338K | 959K | 2.68M | 2.17M | 1.61M | |
Supplemental Operating Expense Items | ||||||
General and Administrative Expenses | 21.17M | 125M | 118M | 96.4M | 74.21M | |
Research And Development Expense From Footnotes | 133M | 226M | 379M | 434M | 451M | |
Net Rental Expense, Total | - | - | 1.35M | 725K | 770K | |
Imputed Operating Lease Interest Expense | - | - | 584K | 310K | 330K | |
Imputed Operating Lease Depreciation | - | - | 767K | 415K | 440K | |
Stock-Based Comp., R&D Exp. (Total) | 3.48M | 49.81M | 65.11M | 27.81M | 13.77M | |
Stock-Based Comp., G&A Exp. (Total) | 1.1M | 40.12M | 45.01M | 19.59M | 6.97M | |
Stock-Based Comp., Other (Total) | - | 429K | - | - | - | |
Total Stock-Based Compensation | 4.57M | 90.36M | 110M | 47.4M | 20.74M |
- Stock Market
- Equities
- 2256 Stock
- Financials Abbisko Cayman Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















